Molecular Insight Pharmaceuticals, Inc. to Present at Jefferies Healthcare Conference

CAMBRIDGE, MA--(Marketwire - June 11, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) will present at the Jefferies 3rd Annual Healthcare Conference in New York City on June 18, 2009 at 4:15 PM, Eastern Standard Time. The Company will be represented by Daniel L. Peters, President and Chief Executive Officer, and John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development. The presentation will include an overview of Molecular Insight’s pipeline of innovative molecular imaging radiopharmaceuticals and molecular radiotherapeutic candidates.

The presentation will be webcast live at http://www.wsw.com/webcast/jeff35/mipi/ and will be archived for 90 days. The webcast will also be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of innovative radiopharmaceuticals in the emerging field of molecular medicine. These novel radiopharmaceuticals will provide important improvements in disease detection and enable the delivery of radiation therapy to widespread metastatic cancers. The Company has focused the initial applications of its proprietary technologies in the areas of cardiology and oncology. Molecular Insight’s lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company’s imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight’s lead molecular radiotherapeutic product candidates, Azedra™, Onalta™, and Solazed™, are being developed for detection and treatment of cancer. In addition, the Company’s discovery efforts continue to identify early-stage candidates -- a product of its in-house scientific expertise and the application of its proprietary platform technologies. For more information, visit http://www.molecularinsight.com.